The Noninvestigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring | Zendy

Aubrey A. Carhill | Zendy; Maria E. Cabanillas | Zendy; Camilo Jiménez | Zendy; Steven G. Waguespack | Zendy; Mouhammed Amir Habra | Zendy; Mimi I. Hu | Zendy; Anita K. Ying | Zendy; Rena VassilopoulouSellin | Zendy; Robert F. Gagel | Zendy; Steven I. Sherman | Zendy; Naifa L. Busaidy | Zendy

Open Access

The Noninvestigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring

Author(s) -

Aubrey A. Carhill,

Maria E. Cabanillas,

Camilo Jiménez,

Steven G. Waguespack,

Mouhammed Amir Habra,

Mimi I. Hu,

Anita K. Ying,

Rena VassilopoulouSellin,

Robert F. Gagel,

Steven I. Sherman,

Naifa L. Busaidy

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-2909

Subject(s) - thyroid cancer , medicine , context (archaeology) , clinical trial , cancer , systematic review , oncology , intensive care medicine , medline , paleontology , biology , political science , law

The increasing use of tyrosine kinase inhibitor therapy outside of the context of the clinical trial for treatment of advanced thyroid cancer has highlighted the need for a systematic approach to the clinical application of these agents in order to improve patient safety and monitoring promote consistency among providers, and ensure compliance with both institutional and industry standards.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research